231 related articles for article (PubMed ID: 12127158)
1. In vitro and in vivo pharmacological profile of 5-[2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl]-4-(4-fluorophenyl)thiazole-2-carboxylic acid amide (NRA0562), a novel and putative atypical antipsychotic.
Funakoshi T; Chaki S; Kawashima N; Suzuki Y; Yoshikawa R; Kumagai T; Nakazato A; Kameo K; Goto M; Okuyama S
Life Sci; 2002 Aug; 71(12):1371-84. PubMed ID: 12127158
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo pharmacological profile of 4-(4-fluorobenzylidene)-1-[2-[5-(4-fluorophenyl)-1H-pyrazol-4-yl] ethyl] piperidine (NRA0161).
Suzuki Y; Funakoshi T; Chaki S; Kawashima N; Ogawa S; Kumagai T; Nakazato A; Komurasaki T; Okuyama S
Life Sci; 2002 Oct; 71(22):2603-15. PubMed ID: 12354579
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic profile of 5-[2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl]-4-(4-fluorophenyl)thiazole-2-carboxylic acid amide (NRA0562) in rats.
Takamori K; Funakoshi T; Hirota S; Chaki S; Kameo K
Life Sci; 2002 Jul; 71(8):947-52. PubMed ID: 12084391
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045).
Okuyama S; Chaki S; Yoshikawa R; Suzuki Y; Ogawa S; Imagawa Y; Kawashima N; Ikeda Y; Kumagai T; Nakazato A; Nagamine M; Tomisawa K
J Pharmacol Exp Ther; 1997 Jul; 282(1):56-63. PubMed ID: 9223539
[TBL] [Abstract][Full Text] [Related]
5. Neuropharmacological profiles of a novel atypical antipsychotic, NRA0562, in rats.
Kawashima N; Funakoshi T; Omura T; Chaki S; Kameo K; Okuyama S
Eur J Pharmacol; 2001 Jun; 423(1):27-33. PubMed ID: 11438303
[TBL] [Abstract][Full Text] [Related]
6. A selective dopamine D4 receptor antagonist, NRA0160: a preclinical neuropharmacological profile.
Okuyama S; Kawashima N; Chaki S; Yoshikawa R; Funakoshi T; Ogawa SI; Suzuki Y; Ikeda Y; Kumagai T; Nakazato A; Nagamine M; Tomisawa K
Life Sci; 1999; 65(20):2109-25. PubMed ID: 10579464
[TBL] [Abstract][Full Text] [Related]
7. Neuropharmacological profile of an atypical antipsychotic, NRA0562.
Hirota S; Kawashima N; Chaki S; Okuyama S
CNS Drug Rev; 2003; 9(4):375-88. PubMed ID: 14647530
[TBL] [Abstract][Full Text] [Related]
8. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
[TBL] [Abstract][Full Text] [Related]
9. In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats.
Chaki S; Funakoshi T; Yoshikawa R; Okuyama S; Kumagai T; Nakazato A; Nagamine M; Tomisawa K
Neuropharmacology; 1999 Aug; 38(8):1185-94. PubMed ID: 10462131
[TBL] [Abstract][Full Text] [Related]
10. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
[TBL] [Abstract][Full Text] [Related]
11. [A study on the pharmacological properties of atypical antipsychotic drugs: in vivo dopamine and serotonin receptor occupancy by atypical antipsychotic drugs in the rat brain].
Matsubara R
Hokkaido Igaku Zasshi; 1993 Jul; 68(4):570-82. PubMed ID: 7687976
[TBL] [Abstract][Full Text] [Related]
12. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography.
Schotte A; Janssen PF; Megens AA; Leysen JE
Brain Res; 1993 Dec; 631(2):191-202. PubMed ID: 7510574
[TBL] [Abstract][Full Text] [Related]
13. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Schizophr Res; 2008 Oct; 105(1-3):224-35. PubMed ID: 18710798
[TBL] [Abstract][Full Text] [Related]
14. Conformationally constrained butyrophenones with affinity for dopamine (D(1), D(2), D(4)) and serotonin (5-HT(2A), 5-HT(2B), 5-HT(2C)) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics.
Raviña E; Casariego I; Masaguer CF; Fontenla JA; Montenegro GY; Rivas ME; Loza MI; Enguix MJ; Villazon M; Cadavid MI; Demontis GC
J Med Chem; 2000 Nov; 43(24):4678-93. PubMed ID: 11101359
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M
J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009
[TBL] [Abstract][Full Text] [Related]
16. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
[TBL] [Abstract][Full Text] [Related]
17. Lu 35-138 ((+)-(S)-3-{1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-3,6-dihydro-2H-pyridin-4-yl}-6-chloro-1H-indole), a dopamine D4 receptor antagonist and serotonin reuptake inhibitor: characterisation of its in vitro profile and pre-clinical antipsychotic potential.
Hertel P; Didriksen M; Pouzet B; Brennum LT; Søby KK; Larsen AK; Christoffersen CT; Ramirez T; Marcus MM; Svensson TH; Di Matteo V; Esposito E; Bang-Andersen B; Arnt J
Eur J Pharmacol; 2007 Nov; 573(1-3):148-60. PubMed ID: 17689529
[TBL] [Abstract][Full Text] [Related]
18. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.
Leysen JE; Janssen PM; Schotte A; Luyten WH; Megens AA
Psychopharmacology (Berl); 1993; 112(1 Suppl):S40-54. PubMed ID: 7530377
[TBL] [Abstract][Full Text] [Related]
19. Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and alpha1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats.
Abekawa T; Honda M; Ito K; Koyama T
Psychopharmacology (Berl); 2003 Sep; 169(3-4):247-56. PubMed ID: 12898123
[TBL] [Abstract][Full Text] [Related]
20. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
Schotte A; Janssen PF; Gommeren W; Luyten WH; Van Gompel P; Lesage AS; De Loore K; Leysen JE
Psychopharmacology (Berl); 1996 Mar; 124(1-2):57-73. PubMed ID: 8935801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
